Dr. Praveen Vemula is a faculty member at the Institute for Stem Cell Biology and Regenerative
Medicine (inStem), Bangalore, India. After obtaining Ph.D. from Indian Institute of Science in
2005, he received postdoctoral training at The City College of New York and Harvard–MIT
Division of Health Sciences and Technology at Harvard Medical School in affiliation with
Brigham and Women’s Hospital. In 2009, the Ewing Marion Kauffman Foundation selected him
as an entrepreneur fellow through whom he received formal training in translational research
Dr. Vemula is a leading researcher in the fields of biomaterials, drug delivery, gene delivery and
translation science. He is an Assistant Investigator at the Institute for Stem Cell Biology and
Regenerative Medicine (inStem), Bangalore. He has published >50 peer-reviewed papers (with >3000 citations) and has given 60 national and international invited lectures and has 20 issued
or pending patents. Several technologies developed by his team have formed the foundation for
multiple products on the market. Based on the technologies he developed, two biotech
companies were formed, Skintifique and Alivio Therapeutics.
Vemula’s work has been discussed in hundreds of newspapers, online websites, television
newscasts, and radio shows around the world including The New York Times, CNN, ABC News,
NBC, Boston Globe, LA Times, BBC, Discovery, National Geographic, The Hindu, The Times of
India, Deccan Herald and many more.
Vemula is an associate editor of Bulletin of Materials Science, a journal of Springer and Indian
Academy of Sciences.
At present, Vemula’s lab is focusing to develop biomaterials and bioengineering concepts to
solve huge unmet clinical needs including protection of transplanted organs, developing
therapeutics for inflammatory/infectious diseases and prevention of pesticide induced lethality.
A significant leap in drug delivery is an autonomous system that titrates the amount of
drug released in response to a disease, for instance, inflammation, ensuring the drug is
released only when needed at therapeutically relevant concentration. Diseases have
inherently fluctuated in nature such as inflammatory and autoimmune diseases, in
particular, pose an enormous challenge to deliver drugs in safe, efficient and
compliant manner. In what follows we will take a brief look at current approaches
about nanotechnology-based therapeutics and with examples taken from our work to
examine how disease-responsive biomaterials have developed to i) improve the
lifetime of the transplanted organs and ii) inflammation-targeted drug delivery to
alleviate inflammatory bowel diseases.